The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis
Source abstract
Abstract
BACKGROUND: Combinations of natural products with low toxicities using tumor-targeting carriers may improve cancer treatment. The combined parthenolide and ginsenoside compound K (CK) within tLyp-1 liposomes, with the aim of improving the efficacy of lung cancer treatment. RESULTS: In vitro studies in A549 human pulmonary adenocarcinoma cells demonstrated that parthenolide/CK tLyp-1 liposomes increased reactive oxygen species levels and induced mitochondrial apoptosis. It enters into cells via receptor-mediated uptake and micropinocytosis, followed by endosomal/lysosomal escape. In vivo studies illustrated that it produced a greater antitumor effect than combined administration of these compounds, with minimal toxicity. CONCLUSION: The findings of this study indicated that combined application of natural products in nanocarriers could offer attractive therapeutic options.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Sesquiterpenes and Asteraceae Studies · Biological Activity of Diterpenoids and Biflavonoids · Natural product bioactivities and synthesis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Hospital Pharmacy, Suqian Branch Jiangsu Province Hospital
Department of Pharmaceutics, State Key Laboratory of Natural Medicines, China Pharmaceutical University
Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese Medicine
Funding
National Natural Science Foundation of China · Natural Science Foundation of China · Jiangsu Youth Medical Talents · Science and Technology Support Project of Suqian
References (38)
Show source-provided references
1. 10.1016/j.addr.2017.04.00610.1016/j.addr.2017.04.006 ↗
2. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
3. 10.1002/cncr.2435910.1002/cncr.24359 ↗
4. 10.1016/j.ejca.2005.12.01110.1016/j.ejca.2005.12.011 ↗
5. Perez-Soler R, Shin DM, Siddik ZH, et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res. 1997;3:373–379.
6. Hartwell JL. Plants used against cancer: a survey. Lawrence, MA: Quarterman; 1982.
7. 10.2174/13894500677605494210.2174/138945006776054942 ↗
8. 10.1016/j.drudis.2013.05.00510.1016/j.drudis.2013.05.005 ↗
9. 10.1016/j.oraloncology.2015.03.00310.1016/j.oraloncology.2015.03.003 ↗
10. 10.2147/OTT.S11725010.2147/OTT.S117250 ↗
11. 10.1159/00045253210.1159/000452532 ↗
12. Zahedpanah M, Shaiegan M, Ghaffari SH, et al. Parthenolide induces apoptosis in committed progenitor AML cell line U937 via reduction in osteopontin. Rep Biochem Mol Biol. 2016;4:82–88.
13. 10.1002/jcp.2486310.1002/jcp.24863 ↗
14. 10.1074/jbc.M115.70059110.1074/jbc.M115.700591 ↗
15. 10.5217/ir.2017.15.2.17410.5217/ir.2017.15.2.174 ↗
16. 10.18632/oncotarget.1558410.18632/oncotarget.15584 ↗
17. 10.1158/1541-7786.MCR-16-010110.1158/1541-7786.MCR-16-0101 ↗
18. 10.1007/s10529-016-2102-710.1007/s10529-016-2102-7 ↗
19. 10.1016/j.biotechadv.2015.03.00110.1016/j.biotechadv.2015.03.001 ↗
20. 10.4014/jmb.1505.0505710.4014/jmb.1505.05057 ↗
21. 10.1007/s12272-014-0340-610.1007/s12272-014-0340-6 ↗
22. 10.1038/cddis.2013.27310.1038/cddis.2013.273 ↗
23. 10.3109/13880209.2015.110114210.3109/13880209.2015.1101142 ↗
24. 10.1111/jphp.1246810.1111/jphp.12468 ↗
25. 10.1016/j.jpba.2015.11.03910.1016/j.jpba.2015.11.039 ↗
26. 10.1016/j.carbpol.2016.08.10010.1016/j.carbpol.2016.08.100 ↗
27. 10.1039/C5NR07724A10.1039/C5NR07724A ↗
28. 10.2147/IJN.S14009610.2147/IJN.S140096 ↗
29. 10.1016/j.nano.2016.10.01710.1016/j.nano.2016.10.017 ↗
30. 10.1124/pr.58.3.1010.1124/pr.58.3.10 ↗
31. 10.1074/jbc.M50320220010.1074/jbc.M503202200 ↗
32. 10.1016/j.canlet.2017.02.00710.1016/j.canlet.2017.02.007 ↗
33. 10.1016/j.synres.2014.07.01110.1016/j.synres.2014.07.011 ↗
34. 10.1080/21691401.2018.145382910.1080/21691401.2018.1453829 ↗
35. 10.1080/21691401.2017.137428110.1080/21691401.2017.1374281 ↗
36. 10.1080/21691401.2018.148927110.1080/21691401.2018.1489271 ↗
37. 10.1093/jnci/djp23510.1093/jnci/djp235 ↗
38. 10.1073/pnas.090820110610.1073/pnas.0908201106 ↗